Our board of directors

Ken is Co-Founder of Moderna Therapeutics, with over three decades of experience in biotechnology, working with Genentech, AZ, Roche, Pfizer, Pictet Biotech Fund, etc. He is currently a senior advisor & business partner with EQT, the leading private equity group in Europe. By realizing the essential and limiting role of DNA templates for the large-scale generation of mRNA vaccines, he played a key role in their acquisition of Aldevron, which lead to the eventual sale in 2021. Trained as a physician-scientist , Ken is a third generation Harvard alumnus ('73) and was formerly the recipient of the Sanders Endowed Chair in the Stem Cell and Regenerative Biology Department at Harvard University. In 2013, he received a Presidential appointment as a Distinguished Professor of the Swedish Research Council and has received several awards for his work at the intersection of biotechnology and Cardiovascular Medicine, including election into the Norwegian Academy of Sciences, Austrian Academy of Sciences, and an honorary Doctor of Science from the University of Edinburgh.

Bernard comes with extensive operational and strategic experience in the pharmaceutical and life sciences industry. He has expertise in manufacturing & distribution, and has an extensive operational background, both in companies and as consultant. He is a pharmacist from the University of Leuven, Belgium and has obtained the qualification of Qualified Person. He was a former QA & Supply Chain Director at Mylan in Belgium, and VP QA EMEAA at Sterigenics, a Sotera company.

Phil is currently CEO of Adimab, a global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies. Prior to Adimab, Phil held positions at various biotechnology companies, including serving as the General Counsel at Alnylam Pharmaceuticals and as Chief Corporate Counsel at Transkaryotic Therapies, Inc. He received his J.D. degree from Columbia University School of Law and his B.A. from Colby College.